Systemic Infusion of Expanded CD133+ Cells and Expanded CD133+ Cell-Derived EVs for the Treatment of Ischemic Cardiomyopathy in a Rat Model of AMI
Myocardial infarction is a leading cause of death among all cardiovascular diseases. Cell therapies using a cell population enriched with endothelial progenitor cells (EPCs), expanded CD133+ cells, have promise as a therapeutic option for the treatment of ischemic areas after infarction. Recently, s...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2019/4802578 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850225306129924096 |
|---|---|
| author | Addeli B. B. Angulski Luiz Guilherme A. Capriglione Fabiane Barchiki Paulo Brofman Marco A. Stimamiglio Alexandra C. Senegaglia Alejandro Correa |
| author_facet | Addeli B. B. Angulski Luiz Guilherme A. Capriglione Fabiane Barchiki Paulo Brofman Marco A. Stimamiglio Alexandra C. Senegaglia Alejandro Correa |
| author_sort | Addeli B. B. Angulski |
| collection | DOAJ |
| description | Myocardial infarction is a leading cause of death among all cardiovascular diseases. Cell therapies using a cell population enriched with endothelial progenitor cells (EPCs), expanded CD133+ cells, have promise as a therapeutic option for the treatment of ischemic areas after infarction. Recently, secreted membrane vesicles, including exosomes and microvesicles, have been recognized as new therapeutic candidates with important roles in intercellular and tissue communication. Expanded CD133+ cells have the ability to produce extracellular vesicles (EVs); however, their effect in the context of the heart is unknown. In the present study, we evaluated the effectiveness of the systemic application of expanded CD133+ cells and expanded CD133+ cell-derived EVs for the treatment of ischemic cardiomyopathy in a rat model of acute myocardial infarction (AMI) and examined the hypothesis that the EVs, because of their critical role in transferring regenerative signals from stem cells to the injured tissues, might elicit an equal or better therapeutic response than the expanded CD133+ cells. We demonstrate that the systemic application of expanded CD133+ cells and EVs has similar effects in infarcted rats. Few animals per group showed improvements in several heart and kidney parameters analyzed, but not significant differences were observed when comparing the groups. The systemic route may not be effective to treat ischemic cardiomyopathy; nonetheless, it may be a beneficial therapy to treat the side effects of AMI such as kidney damage. |
| format | Article |
| id | doaj-art-53cee716612a49d88383ec67b0669eda |
| institution | OA Journals |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-53cee716612a49d88383ec67b0669eda2025-08-20T02:05:24ZengWileyStem Cells International1687-966X1687-96782019-01-01201910.1155/2019/48025784802578Systemic Infusion of Expanded CD133+ Cells and Expanded CD133+ Cell-Derived EVs for the Treatment of Ischemic Cardiomyopathy in a Rat Model of AMIAddeli B. B. Angulski0Luiz Guilherme A. Capriglione1Fabiane Barchiki2Paulo Brofman3Marco A. Stimamiglio4Alexandra C. Senegaglia5Alejandro Correa6Carlos Chagas Institute, Oswaldo Cruz Foundation (FIOCRUZ), Curitiba 81350-010, BrazilCore for Cell Technology-School of Medicine, Pontifical Catholic University of Paraná, Curitiba 80215-901, BrazilCore for Cell Technology-School of Medicine, Pontifical Catholic University of Paraná, Curitiba 80215-901, BrazilCore for Cell Technology-School of Medicine, Pontifical Catholic University of Paraná, Curitiba 80215-901, BrazilCarlos Chagas Institute, Oswaldo Cruz Foundation (FIOCRUZ), Curitiba 81350-010, BrazilCore for Cell Technology-School of Medicine, Pontifical Catholic University of Paraná, Curitiba 80215-901, BrazilCarlos Chagas Institute, Oswaldo Cruz Foundation (FIOCRUZ), Curitiba 81350-010, BrazilMyocardial infarction is a leading cause of death among all cardiovascular diseases. Cell therapies using a cell population enriched with endothelial progenitor cells (EPCs), expanded CD133+ cells, have promise as a therapeutic option for the treatment of ischemic areas after infarction. Recently, secreted membrane vesicles, including exosomes and microvesicles, have been recognized as new therapeutic candidates with important roles in intercellular and tissue communication. Expanded CD133+ cells have the ability to produce extracellular vesicles (EVs); however, their effect in the context of the heart is unknown. In the present study, we evaluated the effectiveness of the systemic application of expanded CD133+ cells and expanded CD133+ cell-derived EVs for the treatment of ischemic cardiomyopathy in a rat model of acute myocardial infarction (AMI) and examined the hypothesis that the EVs, because of their critical role in transferring regenerative signals from stem cells to the injured tissues, might elicit an equal or better therapeutic response than the expanded CD133+ cells. We demonstrate that the systemic application of expanded CD133+ cells and EVs has similar effects in infarcted rats. Few animals per group showed improvements in several heart and kidney parameters analyzed, but not significant differences were observed when comparing the groups. The systemic route may not be effective to treat ischemic cardiomyopathy; nonetheless, it may be a beneficial therapy to treat the side effects of AMI such as kidney damage.http://dx.doi.org/10.1155/2019/4802578 |
| spellingShingle | Addeli B. B. Angulski Luiz Guilherme A. Capriglione Fabiane Barchiki Paulo Brofman Marco A. Stimamiglio Alexandra C. Senegaglia Alejandro Correa Systemic Infusion of Expanded CD133+ Cells and Expanded CD133+ Cell-Derived EVs for the Treatment of Ischemic Cardiomyopathy in a Rat Model of AMI Stem Cells International |
| title | Systemic Infusion of Expanded CD133+ Cells and Expanded CD133+ Cell-Derived EVs for the Treatment of Ischemic Cardiomyopathy in a Rat Model of AMI |
| title_full | Systemic Infusion of Expanded CD133+ Cells and Expanded CD133+ Cell-Derived EVs for the Treatment of Ischemic Cardiomyopathy in a Rat Model of AMI |
| title_fullStr | Systemic Infusion of Expanded CD133+ Cells and Expanded CD133+ Cell-Derived EVs for the Treatment of Ischemic Cardiomyopathy in a Rat Model of AMI |
| title_full_unstemmed | Systemic Infusion of Expanded CD133+ Cells and Expanded CD133+ Cell-Derived EVs for the Treatment of Ischemic Cardiomyopathy in a Rat Model of AMI |
| title_short | Systemic Infusion of Expanded CD133+ Cells and Expanded CD133+ Cell-Derived EVs for the Treatment of Ischemic Cardiomyopathy in a Rat Model of AMI |
| title_sort | systemic infusion of expanded cd133 cells and expanded cd133 cell derived evs for the treatment of ischemic cardiomyopathy in a rat model of ami |
| url | http://dx.doi.org/10.1155/2019/4802578 |
| work_keys_str_mv | AT addelibbangulski systemicinfusionofexpandedcd133cellsandexpandedcd133cellderivedevsforthetreatmentofischemiccardiomyopathyinaratmodelofami AT luizguilhermeacapriglione systemicinfusionofexpandedcd133cellsandexpandedcd133cellderivedevsforthetreatmentofischemiccardiomyopathyinaratmodelofami AT fabianebarchiki systemicinfusionofexpandedcd133cellsandexpandedcd133cellderivedevsforthetreatmentofischemiccardiomyopathyinaratmodelofami AT paulobrofman systemicinfusionofexpandedcd133cellsandexpandedcd133cellderivedevsforthetreatmentofischemiccardiomyopathyinaratmodelofami AT marcoastimamiglio systemicinfusionofexpandedcd133cellsandexpandedcd133cellderivedevsforthetreatmentofischemiccardiomyopathyinaratmodelofami AT alexandracsenegaglia systemicinfusionofexpandedcd133cellsandexpandedcd133cellderivedevsforthetreatmentofischemiccardiomyopathyinaratmodelofami AT alejandrocorrea systemicinfusionofexpandedcd133cellsandexpandedcd133cellderivedevsforthetreatmentofischemiccardiomyopathyinaratmodelofami |